Evonik
In March 2013, the Evonik Birmingham Laboratories site received cGMP certification from the MHRA. The MHRA, a competent UK authority, conducted the audit on behalf of the EMA in the course of registering a new product called SCENESSE for the Evonik client Clinuvel. This is a proprietary, first-in-class photoprotective drug delivered via a subcutaneous, dissolving implant. Upon approval, the drug product will be manufactured at the Evonik Birmingham, Alabama, US, site.
Dr. Jean-Luc Herbeaux, Head of the Health Care Business Line of Evonik, commented: “The certification provides our clients with additional assurance regarding the readiness of this facility to meet the highest quality and regulatory standards. We look forward to further growth in the area of manufacturing of complex dosage forms."
Evonik acquired the Birmingham Laboratories facility in November of 2011. Prior to that, since its commissioning in 2010, it had been used for manufacturing clinical lots for many clients. Today, it serves as the Evonik hub for parenteral drug delivery and commercial drug product manufacture for non-proprietary or customer-proprietary formulations. Birmingham Laboratories focuses primarily on the production of aseptic and terminally sterilised complex dosage forms, including microspheres, drug loaded implants and liposomes. Currently, it is equipped with four suites capable of producing multiple products.
Birmingham Laboratories is also one of two Evonik sites worldwide that manufacture cGMP biodegradable polymers based on poly lactic-co-glycolic acid (PLGA), a critical raw material for advanced drug delivery products and bioresorbable medical devices.
Evonik Industries AG, +49 6181 59-6847, juergen.krauter@evonik.com, www.evonik.com.